The European Union has formally authorized a fourth contract with the US pharmaceutical giant Pfizer and their German lab partner BioNTech to procure up to 300 million doses of their candidate coronavirus vaccine, should it be proven to be safe and effective against the virus.
"In the wake of Monday's promising announcement by BioNTech and Pfizer on the
prospects for their vaccine, I'm very happy to announce today's agreement ...
to purchase 300 million doses," European Commission President Ursula von
der Leyen said in a statement on Wednesday.
Pfizer announced Monday that an early look at data
from its coronavirus vaccine shows it is more than 90%
effective -- a much better than expected efficacy if the trend continues.
The company's CEO's Albert Bourla called it "the
greatest medical advance" in the last 100 years.
According to BioNTech, the EU contract will guarantee the
supply of 200 million doses, with an option to procure an additional 100
million doses. The pharmaceutical company says it expects deliveries to begin
by the end of 2020, pending approval of the vaccine by the European Medical
Agency.
"As a company founded in the heart of Europe, we are
looking forward to supplying millions of people upon regulatory approval,"
BioNTech's CEO Ugur Sahin said in a statement Wednesday.
"Our aim is to develop a safe and effective vaccine to
contribute to bringing this pandemic to an end. Only through joint efforts will
we be able to do so," Sahin added.
The vaccine uses never-before-approved technology called
messenger RNA, or mRNA, to spark an immune response in people who are
vaccinated.
On Tuesday, Sahin said on a call with reporters that said
BioNTech's goal, in cooperation with Pfizer, is to ramp up production of their
vaccine candidate in the hopes of manufacture up to 1.3 billion doses by the
end of 2021, if it receives authorization.
BioNTech and Pfizer plan to ask the US Food and Drug
Administration to authorize emergency use of the vaccine, with that request
coming perhaps as early as next week, he said.
No comments:
Post a Comment